A 72-year-old woman with a seven-year history of Parkinson's disease, characterized by gait instability, rigidity, and postural instability, was admitted to our department for evaluation of recurrent episodes of hypoxemia and altered consciousness. During hospitalization, she experienced recurrent episodes of respiratory failure, prompting the measurement of anti-IgLON5 antibodies, which were found to be positive, leading to a diagnosis of anti-IgLON5 disease. The respiratory failure could not be attributed to vocal cord paralysis or respiratory muscle weakness, leading to the hypothesis that subglottic laryngeal spasm was the cause. Treatment with steroid pulse therapy resulted in improved ventilation. While several cases of anti-IgLON5 disease presenting with respiratory failure due to respiratory muscle weakness have been reported, this case suggests that subglottic laryngeal spasm may also be an underlying cause of respiratory failure in anti-IgLON5 disease.

Download full-text PDF

Source
http://dx.doi.org/10.5692/clinicalneurol.cn-002014DOI Listing

Publication Analysis

Top Keywords

anti-iglon5 disease
16
respiratory failure
16
recurrent episodes
8
respiratory muscle
8
muscle weakness
8
subglottic laryngeal
8
laryngeal spasm
8
respiratory
7
disease
5
case anti-iglon5
4

Similar Publications

Acute onset of anti-IgLON5 disease with meningeal enhancement: a case report.

BMC Neurol

March 2025

Department of Neurology, Liuzhou People's Hospital Affiliated to Guangxi Medical University, No.8 Rd.wenchang Liuzhou, Liuzhou, Guangxi Province, 545000, China.

Article Synopsis
  • Anti-IgLON5 disease is a rare autoimmune condition of the nervous system, characterized by a chronic and progressive course with varying clinical presentations and no specific imaging features.
  • A 78-year-old male initially presented with impaired consciousness and fever, and MRI scans revealed abnormal brain signals and thickening of the dura mater.
  • The patient was diagnosed after finding IgLON5 antibodies in his serum and CSF, and treatment with intravenous methylprednisolone and immunoglobulin therapy led to complete resolution of symptoms and abnormalities within three weeks.
View Article and Find Full Text PDF

A 72-year-old woman with a seven-year history of Parkinson's disease, characterized by gait instability, rigidity, and postural instability, was admitted to our department for evaluation of recurrent episodes of hypoxemia and altered consciousness. During hospitalization, she experienced recurrent episodes of respiratory failure, prompting the measurement of anti-IgLON5 antibodies, which were found to be positive, leading to a diagnosis of anti-IgLON5 disease. The respiratory failure could not be attributed to vocal cord paralysis or respiratory muscle weakness, leading to the hypothesis that subglottic laryngeal spasm was the cause.

View Article and Find Full Text PDF

Serum anti-IgLON5 antibodies, which were tested in 223 patients meeting the diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (PSP/CBS), were negative in all patients. Our study suggests that the frequency of anti-IgLON5 disease is extremely rare in patients with typical presentation of PSP/CBS.

View Article and Find Full Text PDF

Background: Anti-IgLON5 disease is a rare autoimmune neurological disorder with prominent Tau protein deposits in the brainstem and hypothalamus. The aim of this study was to visualize the in vivo distribution patterns of Tau protein in patients with anti-IgLON5 disease using the second-generation Tau PET tracer, Florzolotau (18F) PET imaging.

Methods: Patients diagnosed with anti-IgLON5 disease were enrolled consecutively.

View Article and Find Full Text PDF

IgLON5 autoimmunity secondary to immune checkpoint inhibitor.

J Neuroimmunol

February 2025

Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address:

IgLON5 autoimmunity is characterized by a diverse range of clinical presentations, including neuropsychiatric symptoms, sleep disturbances, gait instability, and bulbar symptoms, that are usually insidiously progressive. While some individuals with specific HLA haplotypes may be more susceptible to developing anti-IgLON5 disease, this antibody is typically not associated with a paraneoplastic etiology nor known to be induced by immune checkpoint inhibitors (ICI). We present a clinical and serological workup of a patient who developed symptoms of IgLON5 autoimmunity following treatment with pembrolizumab.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!